

BAB BIO VENTURES NV  
Form 3  
February 09, 2006

# FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB  
Number: 3235-0104  
Expires: January 31,  
2005  
Estimated average  
burden hours per  
response... 0.5

## INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting  
Person \*

Â BB BIOVENTURES L P

(Last) (First) (Middle)

C/O MPM ASSET  
MANAGEMENT,Â 200  
CLARENDON STREET, 54TH  
FLOOR

(Street)

BOSTON,Â MAÂ 02116

(City) (State) (Zip)

2. Date of Event Requiring  
Statement

(Month/Day/Year)

02/09/2006

3. Issuer Name **and** Ticker or Trading Symbol

ACORDA THERAPEUTICS INC [ACOR]

4. Relationship of Reporting  
Person(s) to Issuer

5. If Amendment, Date Original  
Filed(Month/Day/Year)

(Check all applicable)

\_\_\_\_ Director \_\_\_\_X\_\_ 10% Owner  
\_\_\_\_ Officer \_\_\_\_ Other  
(give title below) (specify below)

6. Individual or Joint/Group  
Filing(Check Applicable Line)  
\_\_\_\_ Form filed by One Reporting  
Person  
\_X\_ Form filed by More than One  
Reporting Person

### Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security  
(Instr. 4)

2. Amount of Securities  
Beneficially Owned  
(Instr. 4)

3. Ownership  
Form:  
Direct (D)  
or Indirect  
(I)  
(Instr. 5)

4. Nature of Indirect Beneficial  
Ownership  
(Instr. 5)

Reminder: Report on a separate line for each class of securities beneficially  
owned directly or indirectly.

SEC 1473 (7-02)

**Persons who respond to the collection of  
information contained in this form are not  
required to respond unless the form displays a  
currently valid OMB control number.**

### Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security  
(Instr. 4)

2. Date Exercisable and  
Expiration Date  
(Month/Day/Year)

3. Title and Amount of  
Securities Underlying  
Derivative Security  
(Instr. 4)

4. Conversion  
or Exercise  
Price of  
Derivative

5. Ownership  
Form of  
Derivative  
Security:

6. Nature of Indirect  
Beneficial Ownership  
(Instr. 5)

# Edgar Filing: BAB BIO VENTURES NV - Form 3

	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Security	Direct (D) or Indirect (I) (Instr. 5)	
Series E-1 Convertible Preferred Stock	Â (1)	Â (1)	Common Stock	125,161 (2)	\$ 13.806 (2)	I	See Footnote (3)
Series E-2 Convertible Preferred Stock	Â (1)	Â (1)	Common Stock	381,965 (2)	\$ 13.806 (2)	I	See Footnote (4)
Series H Convertible Preferred Stock	Â (1)	Â (1)	Common Stock	6,518 (2)	\$ 15.3348 (2)	I	See Footnote (5)
Series I Convertible Preferred Stock	Â (1)	Â (1)	Common Stock	145,330 (2)	\$ 17.1132 (2)	I	See Footnote (6)
Series J Convertible Preferred Stock	Â (1)	Â (1)	Common Stock	981,159 (2)	\$ 7.644 (2)	I	See Footnote (7)

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
BB BIOVENTURES L P C/O MPM ASSET MANAGEMENT 200 CLARENDON STREET, 54TH FLOOR BOSTON,Â MAÂ 02116	Â	Â X	Â	Â
BAB BIO VENTURES LLP C/O MPM ASSET MANAGEMENT 200 CLARENDON STREET, 54TH FLOOR BOSTON,Â MAÂ 02116	Â	Â X	Â	Â
BAB BIO VENTURES NV C/O MPM ASSET MANAGEMENT 200 CLARENDON STREET, 54TH FLOOR BOSTON,Â MAÂ 02116	Â	Â X	Â	Â
MPM ASSET MANAGEMENT INVESTORS 1998 LLC C/O MPM ASSET MANAGEMENT 200 CLARENDON STREET, 54TH FLOOR BOSTON,Â MAÂ 02116	Â	Â X	Â	Â
MPM BIOVENTURES PARALLEL FUND L P C/O MPM ASSET MANAGEMENT 200 CLARENDON STREET, 54TH FLOOR BOSTON,Â MAÂ 02116	Â	Â X	Â	Â
MPM BIOVENTURES I LP C/O MPM ASSET MANAGEMENT 200 CLARENDON STREET, 54TH FLOOR BOSTON,Â MAÂ 02116	Â	Â X	Â	Â
	Â	Â X	Â	Â

MPM BIO VENTURES I LLC  
C/O MPM ASSET MANAGEMENT  
200 CLARENDON STREET, 54TH FLOOR  
BOSTON, MA 02116

GADICKE ANSBERT  
C/O MPM ASSET MANAGEMENT  
200 CLARENDON STREET, 54TH FLOOR  
BOSTON, MA 02116

^ ^ X ^ ^

EVNIN LUKE  
C/O MPM ASSET MANAGEMENT  
200 CLARENDON STREET, 54TH FLOOR  
BOSTON, MA 02116

^ ^ X ^ ^

## Signatures

By Ansbert Gadicke, manager director of BAB BioVentures NV, the general partner of BAB BioVentures L.P., the general partner of BB BioVentures L.P. /s/ Ansbert Gadicke

02/09/2006

\_\_Signature of Reporting Person

Date

By Ansbert Gadicke, manager director of BAB BioVentures NV, the general partner of BAB BioVentures L.P. /s/ Ansbert Gadicke

02/09/2006

\_\_Signature of Reporting Person

Date

By Ansbert Gadicke, manager director of BAB BioVentures NV /s/ Ansbert Gadicke

02/09/2006

\_\_Signature of Reporting Person

Date

By Michael Steinmetz, manager of MPM Asset Management Investors 1998 LLC /s/ Michael Steinmetz

02/09/2006

\_\_Signature of Reporting Person

Date

By Michael Steinmetz, manager of MPM BioVentures I LLC, the general partner of MPM BioVentures I L.P., the general partner of MPM BioVentures Parallel Fund, L.P. /s/ Michael Steinmetz

02/09/2006

\_\_Signature of Reporting Person

Date

By Michael Steinmetz, manager of MPM BioVentures I LLC, the general partner of MPM BioVentures I L.P. /s/ Michael Steinmetz

02/09/2006

\_\_Signature of Reporting Person

Date

By Michael Steinmetz, manager of MPM BioVentures I LLC /s/ Michael Steinmetz

02/09/2006

\_\_Signature of Reporting Person

Date

/s/ Luke Evnin

02/09/2006

\_\_Signature of Reporting Person

Date

/s/ Ansbert Gadicke

02/09/2006

\_\_Signature of Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The convertible preferred stock is convertible at any time, at the holder's discretion, and has no expiration date.

### Edgar Filing: BAB BIO VENTURES NV - Form 3

- (2) The number of shares underlying convertible preferred stock in column 3 of Table II represents the number of shares of Common Stock of the Issuer that the convertible preferred stock will automatically convert into upon the closing of the Issuer's initial public offering.
- These shares are held as follows: 114,686 shares by BB BioVentures, L.P. ("BBBV"), 1,439 shares by MPM Asset Management Investors 1998 LLC ("AM 1998") and 9,036 shares by MPM BioVentures Parallel Fund, L.P. ("BV PF"). MPM BioVentures I, L.P. ("BV I") and MPM BioVentures I LLC ("BV I LLC") are the direct and indirect general partners of BV PF. BAB BioVentures L.P. ("BAB BV"), BAB BioVentures, N.V. ("BAB NV") and BV I LLC are the direct and indirect general partners of BB BV. Luke Evnin, Ansbert Gadick and Michael Steinmetz are the managers of AM 1998 and BV I LLC. Each member of the group disclaims beneficial ownership of all such shares except to the extent of their respective proportionate pecuniary interests therein.
- (3) These shares are held as follows: 349,996 shares by BBBV, 4,392 shares by AM 1998 and 27,577 shares by BV PF. BV I and BV I LLC are the direct and indirect general partners of BV PF. BAB BV, BAB NV and BV I LLC are the direct and indirect general partners of BB BV. Luke Evnin, Ansbert Gadick and Michael Steinmetz are the managers of AM 1998 and BV I LLC. Each member of the group disclaims beneficial ownership of all such shares except to the extent of their respective proportionate pecuniary interests therein.
- (4) These shares are held as follows: 5,674 shares by BBBV, 74 shares by AM 1998 and 770 shares by BV PF. BV I and BV I LLC are the direct and indirect general partners of BV PF. BAB BV, BAB NV and BV I LLC are the direct and indirect general partners of BB BV. Luke Evnin, Ansbert Gadick and Michael Steinmetz are the managers of AM 1998 and BV I LLC. Each member of the group disclaims beneficial ownership of all such shares except to the extent of their respective proportionate pecuniary interests therein.
- (5) These shares are held as follows: 124,840 shares by BBBV, 1,670 shares by AM 1998 and 18,820 shares by BV PF. BV I and BV I LLC are the direct and indirect general partners of BV PF. BAB BV, BAB NV and BV I LLC are the direct and indirect general partners of BB BV. Luke Evnin, Ansbert Gadick and Michael Steinmetz are the managers of AM 1998 and BV I LLC. Each member of the group disclaims beneficial ownership of all such shares except to the extent of their respective proportionate pecuniary interests therein.
- (6) These shares are held as follows: 870,999 shares by BBBV, 11,283 shares by AM 1998 and 98,877 shares by BV PF. BV I and BV I LLC are the direct and indirect general partners of BV PF. BAB BV, BAB NV and BV I LLC are the direct and indirect general partners of BB BV. Luke Evnin, Ansbert Gadick and Michael Steinmetz are the managers of AM 1998 and BV I LLC. Each member of the group disclaims beneficial ownership of all such shares except to the extent of their respective proportionate pecuniary interests therein.
- (7)

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.